Tejnaksh Healthcare
- Market cap
- ₹ 24 Cr.
- P/E
- 20.6x
- P/B
- 0.85x
- 52-week range
- 10.65 – 18.6
- ROE
- 5%
- ROCE
- 6.3%
- Dividend yield
- 0%
- Debt / equity
- 0.01
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Tejnaksh Healthcare Limited is an India-based holding company, which is engaged in the healthcare services and pharmacies business. The Company is focused on the provision of hospital and healthcare services in Mumbai and other parts of Maharashtra. The Company operates through one segment: Health care services. The Company's domains include Multi-specialty Hospital, Super Specialty Hospital, Pathology Lab, research and development, Pharmaceuticals, Healthcare Equipment, Super Specialty Training Institutes, Stone Analysis Lab Education Institutes, Education Institutes, and Simulation Institute. Its Healthcare Equipment includes a stone manipulation simulator, Fluoroscopy guided simulator, an ultrasound guided perc simulator, Percutaneous Nephrolithotomy (PCNL) logic simulator, turp simulator, and a radiation-free perc simulator. It provides healthcare services at approximately 13 urology clinics, four urology hospitals, and two dental superspecialist clinics.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Tejnaksh Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)20.6 against a typical 21: cheaper than most peers (1st = cheapest).16th of 34
- Sales growth+0.4% against a typical +19.1% from a year earlier.28th of 31
- Profit growth+23.8% against a typical +25.2% from a year earlier.13th of 24
- Share price, 3 months−8.9% against a typical −5.5%.19th of 33
- Size₹ 23.9 Cr. market value against a typical ₹ 83 Cr. (1st = largest).25th of 34
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Expenses | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| OPM % | 36.6% | 34.1% | 31.2% | 34.6% | 34.4% | 35.7% | 22.1% | 22.7% | 25.8% | 26.3% | 27.8% | 26% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| Tax % | 26.8% | 25% | 26.2% | 25% | 21.7% | 42.3% | 28.3% | 28.6% | 33.3% | 19.4% | 32.7% | 37.2% |
| Net Profit | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS in Rs | 0.29 | 0.27 | 0.25 | 0.3 | 0.31 | 0.3 | 0.25 | 0.12 | 0.15 | 0.15 | 0.18 | 0.13 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 9%
- 5 Years
- −2%
- 3 Years
- −3%
- TTM
- −13%
- 10 Years
- −1%
- 5 Years
- −10%
- 3 Years
- −10%
- TTM
- −38%
- 10 Years
- 3%
- 5 Years
- −22%
- 3 Years
- −27%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Tejnaksh Healthcare | ₹ 12.50 | ₹ 24 Cr. | 20.6x | 0.9x | 5% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Ashish Vishwas Rawandale
- Executive Chairman of the Board, Managing Director
- Ramesh Daulat Kuwar
- Chief Financial Officer
- Shaikh Afrinas
- Compliance Officer, Company Secretary
- Yaser Ahmedd
- Resident Urology
- Gautam Ladumor
- Resident Urology
- Lokesh Patni
- Resident Urology
Prices are delayed and for information only. Nothing on this page is investment advice.